TY - JOUR
T1 - Prevalence of Symptoms ≤12 Months After Acute Illness, by COVID-19 Testing Status Among Adults ' United States, December 2020-March 2023
AU - Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) Group
AU - Montoy, Juan Carlos C.
AU - Ford, James
AU - Yu, Huihui
AU - Gottlieb, Michael
AU - Morse, Dana
AU - Santangelo, Michelle
AU - O'Laughlin, Kelli N.
AU - Schaeffer, Kevin
AU - Logan, Pamela
AU - Rising, Kristin
AU - Hill, Mandy J.
AU - Wisk, Lauren E.
AU - Salah, Wafah
AU - Idris, Ahamed H.
AU - Huebinger, Ryan M.
AU - Spatz, Erica S.
AU - Rodriguez, Robert M.
AU - Klabbers, Robin E.
AU - Gatling, Kristyn
AU - Wang, Ralph C.
AU - Elmore, Joann G.
AU - McDonald, Samuel A.
AU - Stephens, Kari A.
AU - Weinstein, Robert A.
AU - Venkatesh, Arjun K.
AU - Saydah, Sharon
N1 - Publisher Copyright:
© 2023 Department of Health and Human Services. All rights reserved.
PY - 2023/8/11
Y1 - 2023/8/11
N2 - To further the understanding of post-COVID conditions, and provide a more nuanced description of symptom progression, resolution, emergence, and reemergence after SARS-CoV-2 infection or COVID-like illness, analysts examined data from the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE), a prospective multicenter cohort study. This report includes analysis of data on self-reported symptoms collected from 1,296 adults with COVID-like illness who were tested for SARS-CoV-2 using a Food and Drug Administration-approved polymerase chain reaction or antigen test at the time of enrollment and reported symptoms at 3-month intervals for 12 months. Prevalence of any symptom decreased substantially between baseline and the 3-month follow-up, from 98.4% to 48.2% for persons who received a positive SARS-CoV-2 test results (COVID test-positive participants) and from 88.2% to 36.6% for persons who received negative SARS-CoV-2 test results (COVID test-negative participants). Persistent symptoms decreased through 12 months; no difference between the groups was observed at 12 months (prevalence among COVID test-positive and COVID test-negative participants = 18.3% and 16.1%, respectively; p>0.05). Both groups reported symptoms that emerged or reemerged at 6, 9, and 12 months. Thus, these symptoms are not unique to COVID-19 or to post-COVID conditions. Awareness that symptoms might persist for up to 12 months, and that many symptoms might emerge or reemerge in the year after COVID-like illness, can assist health care providers in understanding the clinical signs and symptoms associated with post-COVID-like conditions.
AB - To further the understanding of post-COVID conditions, and provide a more nuanced description of symptom progression, resolution, emergence, and reemergence after SARS-CoV-2 infection or COVID-like illness, analysts examined data from the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE), a prospective multicenter cohort study. This report includes analysis of data on self-reported symptoms collected from 1,296 adults with COVID-like illness who were tested for SARS-CoV-2 using a Food and Drug Administration-approved polymerase chain reaction or antigen test at the time of enrollment and reported symptoms at 3-month intervals for 12 months. Prevalence of any symptom decreased substantially between baseline and the 3-month follow-up, from 98.4% to 48.2% for persons who received a positive SARS-CoV-2 test results (COVID test-positive participants) and from 88.2% to 36.6% for persons who received negative SARS-CoV-2 test results (COVID test-negative participants). Persistent symptoms decreased through 12 months; no difference between the groups was observed at 12 months (prevalence among COVID test-positive and COVID test-negative participants = 18.3% and 16.1%, respectively; p>0.05). Both groups reported symptoms that emerged or reemerged at 6, 9, and 12 months. Thus, these symptoms are not unique to COVID-19 or to post-COVID conditions. Awareness that symptoms might persist for up to 12 months, and that many symptoms might emerge or reemerge in the year after COVID-like illness, can assist health care providers in understanding the clinical signs and symptoms associated with post-COVID-like conditions.
UR - http://www.scopus.com/inward/record.url?scp=85167718086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85167718086&partnerID=8YFLogxK
U2 - 10.15585/mmwr.mm7232a2
DO - 10.15585/mmwr.mm7232a2
M3 - Article
C2 - 37561663
AN - SCOPUS:85167718086
SN - 0149-2195
VL - 72
SP - 859
EP - 865
JO - Morbidity and Mortality Weekly Report
JF - Morbidity and Mortality Weekly Report
IS - 32
ER -